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ABSTRACT
A new approach is described for delivering small interfering RNA (siRNA) into cancer cells by noncovalently 
complexing unmodifi ed siRNA with pristine single-walled carbon nanotubes (SWCNTs). The complexes were 
prepared by simple sonication of pristine SWCNTs in a solution of siRNA, which then served both as the 
cargo and as the suspending agent for the SWCNTs. When complexes containing siRNA targeted to hypoxia-
inducible factor 1 alpha (HIF-1 ) were added to cells growing in serum containing culture media, there was 
strong specific inhibition of cellular HIF-1  activity. The ability to obtain a biological response to SWCNT /
siRNA complexes was seen in a wide variety of cancer cell types. Moreover, intratumoral administration of 
SWCNT- HIF-1  siRNA complexes in mice bearing MiaPaCa-2 /HRE tumors signifi cantly inhibited the activity 
of tumor HIF-1 . As elevated levels of HIF-1  are found in many human cancers and are associated with 
resistance to therapy and decreased patient survival, these results imply that SWCNT /siRNA complexes may 
have value as therapeutic agents. 
KEYWORDS 
siRNA, single-walled carbon nanotubes, anti-cancer therapy, in vivo delivery agent
Introduction
The hypoxic microenvironment present in rapidly 
proliferating solid tumors makes them among the 
most aggressive and difficult tumors to treat [1, 2]. 
Unlike the balance achieved in normal tissues, the 
consumption of oxygen in these tumors exceeds 
oxygen delivery from tumor blood vessels [3]. 
Clinically, treatment failure results from the resistance 
of hypoxic cancer cells to both chemotherapy [4] and 
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radiotherapy [5, 6]. 
Hypoxia-inducible factor 1 alpha (HIF-1 ) is a 
transcription factor whose activity is increased in 
human cancers in response to intratumoral hypoxia 
[7, 8]. HIF-1  plays important roles in many aspects 
of cancer biology, including cell proliferation, 
angiogenesis, invasion, and glycolysis, through the 
transcriptional regulation of a large number of genes 
[9]. The significance of the contribution of HIF-1  
to tumor growth is well documented [10 13], and 
mouse xenograft studies have clearly demonstrated 
that the inhibition of HIF-1  activity suppresses 
tumor growth [6, 11, 14]. HIF-1  is thus an attractive 
target for the development of anti-cancer agents. 
Several small-molecule inhibitors of HIF-1  have 
been identified, but their selectivity remains 
undefined. Selective inhibition of HIF-1  activity is 
an attractive approach to suppress tumor growth that 
may be achievable using siRNA as the therapeutic 
agent. 
Exogenously synthesized, 19 to 22 base pair (bp) 
double-stranded small interfering RNA (siRNA) can 
activate the endogenous RNA interference (RNAi) 
pathway within mammalian cells and serve as a 
powerful tool for selective gene silencing. While 
RNAi holds great promise for targeted cancer 
therapy [15], one of the key challenges is its delivery 
into tumor cells. 
Single-walled carbon nanotubes (SWCNTs) are a 
new class of nanomaterials with signifi cant biological 
potential. They are possible vehicles for delivering 
siRNA into mammalian cells, as they are capable of 
transporting various biological molecules into cancer 
cells through endocytosis, with negligible toxicity to 
the cells [16 20]. However, before they can be used 
in biomedical applications, the hydrophobic pristine 
SWCNTs must be converted into a stable suspension 
in aqueous solution [21]. This can be accomplished 
by noncovalently coating SWCNTs with surfactants 
or polymers, or by covalently functionalizing their 
side walls with suitable water-soluble groups [22
26]. SWCNTs functionalized with covalently bound 
siRNA have been used to deliver siRNA into cancer 
cells in both in vitro tissue culture and in tumor-
bearing mice [17, 27, 19]. In addition, SWCNTs have 
been noncovalently coated with phospholipids 
that were covalently linked to siRNA [27]. These 
complexes were then delivered into cancer cells, 
T-cells, and human primary cells to knock down 
targeted genes. In both of these approaches, an 
intracellular chemical reaction is subsequently 
needed to break the covalent link and release the 
siRNA cargo [28].
In the present study we have adopted an 
alternative approach in which unmodified siRNA 
serves both to noncovalently solubilize SWCNTS and 
also acts as the cargo. This method was suggested by 
the reported ability of single-stranded DNA (ssDNA) 
to coat pristine SWCNTs and give stable aqueous 
suspensions [29 31]. The DNA in such complexes 
apparently forms a helical wrapping around the 
SWCNTs in which the bases interact closely with 
the hydrophobic surface of the nanotubes while the 
sugar-phosphate groups are exposed to water [29]. 
Optimum binding was observed to be dependent 
on base composition [32], with the best SWCNT 
solubilization obtained with a sequence containing 
alternating G and T and total lengths from 20 to 90 
bp. Although the nanotube-coating interactions in 
such complexes must differ from those containing 
a double-stranded oligonucleotide such as siRNA, 
formation of our SWCNT /siRNA noncovalent 
complexes also required only simple ultrasonic 
agitation rather than chemical reactions. We found 
that the siRNA in these complexes retained its 
biological activity and readily entered cells even 
in the presence of serum as demonstrated by 
observation of the RNAi response in exposed cell 
culture. In addition, intratumoral administration of 
SWCNT /siRNA complexes targeting HIF-1  was 
found to significantly reduce HIF-1  activity in 
tumor-bearing mice. Our study demonstrates the 
potential for using pristine SWCNTs solubilized by 
siRNA as a therapeutic agent for cancer treatment. 
1. Experimental
1.1   Preparation of noncovalent complexes of 
SWCNTs with siRNA
SWCNTs were produced through the high-pressure 
carbon monoxide (HiPco)  process  [33] .  Raw 
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HiPco SWCNT product was added to an aqueous 
buffer solution (100 mM KCL, 30 mM HEPES-
KOH [pH 7.5], 1mM MgCL2) containing 20 mol /
L solubilized pooled siRNA [ (siRNA targeting 
HIF-1  (HIF-1 ) 5’-CCUGUGUCUAAAUCUG
AAC-3’, 5’CUACCUUCGUGAUUCUGUUU-3’, 
G C A C A A U A G A C A G C G A A A C - 3 ’ , 
5’-CUACUUUCUUAAUGGCUUA),  polo-l ike 




superfamily protein (Kif11), 5’-CGUCUUUAGAU 
UCCUAUAU-3’, 5’-GUUGUUCCUACUUCAGAUA
-3’, 5’-GUCGUCUUUAGAUUCCU AU-3’, 5’-GAUC
UACCGAAAGAGUCAU-3’], non-targeting siRNA 
5’-UAGCGACAUU UGUGUAGUU-3’ or siTox, 
which were all purchased from Dharmacon Inc, IL. 
When siTox is introduced into the cell it does not 
activate the RNAi response but instead induces the 
interferon response resulting in the non-specific 
killing of the cell; it therefore serves as a good 
positive control in the determination of transfection 
effi ciency. This mixture was sonicated (Sonics, Vibra-
cell) at 25 °C using two 15 s pulses at settings of 130 W, 
20 kHz, and 40% amplitude. The sonicated samples 
were then centrifuged at 15,000 g for 5 min. The 
resulting pellet comprised of bundled SWCNTs was 
discarded and the supernatant was transferred into a 
clean tube and centrifuged for an additional 1 min with 
the same settings. The resulting supernatant contained 
SWCNTs noncovalently suspended by coatings of 
adsorbed siRNA. Near-infrared (NIR) fluorescence 
spectroscopy indicated that these samples contained 
predominantly individually suspended SWCNTs rather 
than nanotube aggregates. These SWCNT /siRNA 
complexes were stable and retained their biological 
activity following storage for 30 days at 4 °C. Longer 
periods of time have not been tested but we predict that 
our SWCNT /siRNA complexes will retain biological 
activity for longer periods of storage at 4 °C.
1.2   Cell culture and cellular incubation with 
SWCNT /siRNA complexes
MiaPaCa2-HRE (a pancreatic cell line with an 
HIF-1 / luciferase reporter) cells were incubated 
in growth media consist ing of  high-glucose 
DMEM supplemented with 10% fetal calf serum 
(all reagents from HyClone). To determine the 
internalization rate of non-targeting siRNA-
solubilized SWCNTs, 50 μL of the complex (final 
SWCNT concentration ~1.25 mg / L) was added to 
cells (~2 × 105 cells / well) that had been incubated 
for 18 h in 1 mL of media in a 6-well  plate. 
Incubation with the SWCNT / siRNA complex 
was continued for 1, 3, and 6 h. After incubation, 
media was removed from the wells, the cells 
were washed once in phosphate buffered saline 
(PBS) and were then detached from the surface by 
adding 0.25% trypsin (Invitrogen). The detached 
cells were washed with growth media to inactivate 
the trypsin and then washed again with PBS. These 
cells were resuspended in 1 mL of growth media, 
transferred onto a circular glass cover slip in a well 
of a new 6-well plate, and incubated at 37 °C in a 
humid environment for ~20 h. NIR fluorescence 
microscopy was then used to identify internalized 
SWCNTs. 
To investigate the biological activities of SWCNT /
siRNA complexes, 20 μL of each sample was added 
to cells (~2 ×105 cells /well) in 100 μL of media 
containing 10% FCS in 96-well plates. The plates 
were incubated at 37 °C in a humidifi ed chamber for 
~18 h prior to, and for 72 h following, addition of the 
complexes. To determine the ability of the complexes 
to suppress HIF-1  activity or silence the HIF-1  
protein, treated cells incubated under normoxia for 
72 h were incubated for a further 18 h under hypoxic 
conditions (1% oxygen).
1.3   Cell viability
C e l l  p ro l i f e r a t i o n  re a g e n t  ( W S T- 1 ,  R o c h e , 
Mannheim, Germany) was added to cells in media 
to a fi nal concentration of 10%, and the cells were 
incubated for 30 min at 37 °C in a humidified 
incubator. The absorbance of the sample was then 
measured relative to a background control using 
a microplate reader (POLARstar OPTIMA, BMG 
Labtech) at 420 480 nm.
1.4   Reporter assay
The MiaPaCa2-HRE cell line used in this study was 
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generated in order to stably express the promoter 
sequence of a target gene of HIF-1  comprising the 
HIF-1  binding hypoxia response element (HRE) 
fused to the luciferase gene. At the end of the 
experiment, 100 μL of media was removed from 
each well of the 96-well plate and replaced with 50 
μL of the luciferase reagent (25 mM tricine, 0.5 mM 
EDTA-NA2, 0.54 mM sodium triphosphate, 16.3 
mM MgSO4·7H2O, 0.3% Triton X-100, 0.1% w /v 
dithiothreitol, 1.2 mM ATP, 50 mM luciferin and 
270 mM coenzyme A). The plates were incubated at 
room temperature for 5 min. Sample luminescence 
was measured relative to a background control using 
a microplate reader (POLARstar OPTIMA, BMG 
Labtech). 
1.5   Spectroscopy and microscopy of SWCNTs
The NIR emission spectrum of the siRNA-suspended 
SWCNTs was measured using 658 nm excitation 
in a  model  NS1 NanoSpectralyzer  (Applied 
NanoFluorescence, Houston, TX). NIR fluorescence 
microscopy was performed using a custom-built 
apparatus containing diode laser excitation sources 
emitting at 658 and 785 nm [34]. Individual SWCNTs 
internalized into cells were imaged with a custom-
built NIR fluorescence microscope using 785 nm 
excitation, a 60× oil-immersion objective, and a 946 
nm long-pass fi lter in the collection path. Bright fi eld 
images were taken using the 60×  objective.
1.6   Statistical analysis
S t a t i s t i c a l  a n a l y s e s  w e re  p e r f o r m e d  w i t h 
commercially available software. We used single 
regression analysis to assess the ratio of HIF-1  
activity after treatment with 100 μL sample volume; 
SWCNT concentration ~4 mg /L; siRNA concentration 
~2  μM, with the percentage luciferase expression 
after SWCNT /siRNA treatment as the dependent 
variable. Student’s t-tests were used to compare the 
ratio of luciferase intensity within the tumor between 
mice treated with SWCNT /siRNA. Comparisons of 
mice treated with siRNA targeting HIF-1  (siHIF), 
SWCNT /non-targeting siRNA (SWCNT /SC), or 
siRNA targeting HIF-1  (siHIF) were computed by 
two-way ANOVA. Statistical signifi cance was defi ned 
as a P value of <0.05.
1.7   Animal studies 
1.7.1   Testing of the biological activity of the SWCNT /
siRNA complexes in 0.9% saline solution
SWCNTs were complexed with 20 μM of siRNA 
targeting polo-like kinase1 (PLK1) in a 0.9% NaCl 
solution using the procedure described above. A 20 
μL portion of each sample was added to cells (~ 2 ×
105 cells /well) in 100 μL of media containing 10% FCS 
in 96-well plates. The treated cells were incubated at 
37 °C in a humid chamber for 72 h and their viability 
was determined by the WST-1 assay. 
1.7.2   Injection of mice with MiaPaCa-2 /HRE pancreatic 
cancer cells
The cells were grown in humidifi ed 95% air, 5% CO2 
at 37 °C in DMEM supplemented with 10% FCS. 
Cells (107) in log cell growth were suspended in 0.1 
mL Matrigel (Becton Dickinson Biosciences, Palo 
Alto, CA) and injected subcutaneously (s.c.) into the 
flanks of female Swiss athymic nude nu /nu mice 
(Department of Experimental Radiation Oncology, 
University of Texas M. D. Anderson Cancer Center , 
Houston, TX). Tumor diameters at right angles (dshort 
and dlong) were measured twice weekly with electronic 
calipers and converted to volume by the formula [35]: 
volume =d2short ×dlong /2. When the tumors reached 
150 mm3, the mice were stratified into groups of 
eight animals having approximately equal mean 
tumor volumes. Intratumoral administration of the 
SWCNT /siRNA complexes was then performed 
twice per week for three weeks (100 μL sample 
volume; SWCNT concentration ~4 μM; siRNA 
concentration ~2 μM). The intratumoral injections 
were administered with the mice positioned dorsally 
and their tumors divided into four quadrants; each 
injection was administered in a new quadrant using 
a clockwise rotation. Tumor volume was measured 
twice weekly until the tumor reached 1500 mm3 or 
more or became necrotic, at which time the animals 
were euthanized. 
1.8   Detecting luciferase expression in vivo: 
Bioluminescence imaging
After 20 days of tumor development, mice were 
imaged twice weekly using the IVIS Lumina 
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(Caliper Life Sciences). Mice were pair-matched 
into groups according to their tumor volumes. 
Before imaging, D-luciferin (Caliper Life Sciences) 
was given to each mouse via intraperitoneal (i.p.) 
injection at a dose of 150 mg / kg and allowed to 
distribute for 5 min. After they were anesthetized 
in the chamber with 3% isoflurane, mice were 
imaged using a 12.5 cm field of view and a 15 s 
exposure time. Their respective bioluminescence 
intensities were determined by calculating the 
photon fl ux using Living Image software (version 
3.0). Photon flux was represented as photons /
( s · cm2 · sr) in the region of interest (ROI) and 
surrounding bioluminescence signal provided by 
the tumor. The ROIs were then used to determine 
the photon fl ux, expressed as percent photon fl ux 
of vehicle control values [36].
1.9   Western blotting
Cell pellets were resuspended in modified RIPA 
lysis  buffer  (10 mM NaCL,  1%  NP-40,  0 .5% 
sodium deoxycholate, 0.1%  SDS, 50 mM tris-
hydrochloric acid [pH 7.5] with inhibitors (20 mg /mL 
aprotinin, 1 mM sodium fluoride, 2 mM sodium 
orthovanadate, 0.5 mM phemylmethanesulfonyl 
fluoride and 250 mg / mL benzamidine) in ice 
for 30 min and centrifuged at 15,000 g  for 30 
min to collect whole cell lysates. The lysates (50
60 μg) were run on 10% SDS polyacrylamide 
electrophoresis (PAGE) gels and transferred to 
a polyvinylidene difluoride membrane. Western 
blotting was performed with specific primary 
antibodies and peroxidase-conjugated AffiniPure 
anti-mouse and anti-rabbit secondary antibodies 
( J a c k s o n  I m m u n o R e s e a r c h  L a b o r a t o r i e s ) . 
Proteins were visualized with ECL Plus enhanced 
c h e m i l u m i n e s c e n c e  r e a g e n t s  ( A m e r s h a m 
Biosciences, Piscataway, NJ).
2. Results and discussion
2.1   Suspension of pristine SWCNTs in siRNA
Nucleic acids, including single-stranded DNA and 
RNA, have previously been shown to be capable 
of suspending and dispersing SWCNTs in water 
through noncovalent association [29]. We found 
that sonication of pristine SWCNTs in aqueous 
buffer in the absence of siRNA failed to produce a 
stable suspension (Fig. 1 (a)). However, equivalent 
processing in the presence of siRNA gave stable, 
homogeneous suspensions (Fig. 1 (b)). As shown in 
Fig. 1 (c), these suspensions displayed strong near-
infrared (NIR) fluorescence between ~900 and 1600 
nm, which is characteristic of individual but not 
aggregated SWCNTs [37]. We conclude that pristine, 
individualized SWCNTs are made water-compatible 
by coating with siRNA. 
Figure 1 Photographs of pristine single-walled carbon nanotubes 
(SWCNTs) dispersed in 5× siRNA buffer: (a) SWCNTs alone; (b) 
siRNA-solubilized SWCNT solution; (c) normalized emission spectra 
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2.2   Rapid internalization of siRNA-solubilized 
pristine SWCNTs into pancreatic cancer cells
We next investigated whether siRNA-coated 
SWCNTs could be internalized into cells in tissue 
culture. Previous studies indicate that covalently 
modified SWCNTs can enter cells rather quickly. 
We exposed MiaPaCa2-HRE cultures to SWCNT /
siRNA complexes for 1, 3, and 6 h in order to monitor 
internalization. NIR fluorescence microscopy of the 
treated cells clearly revealed internalized SWCNTs 
(Fig. 2). These were identifi ed by their characteristic 
emission wavelengths and their strong dependence 
of emission intensity on excitation beam polarization. 
In addition, NIR fluorescent particles were found 
only in cells incubated with suspended SWCNTs 
and not in SWCNT-free control samples. As the 
sample area irradiated by the laser beam was smaller 
than the image field, some cells in each image do 
not show NIR emission even though they contain 
internalized SWCNTs. We observed that incubation 
for 1 h with the SWCNT /siRNA complexes resulted 
in SWCNT uptake by approximately 40% of cells. 
Incubation for 3 h or 6 h resulted in nanotube uptake 
by larger fractions of cells, and the average SWCNT 
content per cell also increased with incubation time. 
Although the concentration of internalized nanotubes 
varied substantially from cell to cell, after incubation 
for 6 h more than 90% of the cells showed detectable 
SWCNTs.
2.3   Delivery of siRNA capable of inducing a 
biological response by internalized SWCNTs
Having found that brief sonication successfully 
produced SWCNT /siRNAi complexes capable of 
cellular internalization, we performed experiments to 
see whether the internalized siRNA was biologically 
active. We sonicated a mixture of pristine SWCNTs 
and siTox (known to induce interferon-dependent 
killing) and added 20 μL of the complex (containing 
5 mg /L SWCNTs and 5 μM siTox) to MiaPaCa-HRE 
(human pancreatic cancer) cells growing in a 96-well 
Figure 2 Bright fi eld and NIR images of incubated cells showing internalized SWCNTs. MiaPaCa2-HRE pancreatic cells were incubated with 
SWCNT / siRNA complexes for the times indicated, harvested by trypsinization, washed and re-seeded on circular glass cover slips placed 
in a well of a 6-well plate. After 20 h of incubation at 37 °C, cells growing on the cover slips were imaged in bright fi eld and by NIR 
fl uorescence microscopy. In the overlaid images, NIR emission from internalized SWCNTs is displayed in green. No SWCNTs were detected 
in untreated cells 
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plate. Each well contained 100 μL of medium with 
10% FCS. Controls included untreated cells, and 
cells treated with 20 μL of a complex of SWCNT 
and non-targeting siRNA (SWCNT /SC) (containing 
5 mg /L SWCNTs and 5 μM siSC), 20 μL of SWCNTs 
solubilized by 10% FCS, buffer alone, and free 
uncomplexed siTox (final concentration 5 μM). At 
72 h after treatment, we observed a ~90% decrease 
in viability of cells treated with the SWCNT /siTox 
complex (Fig. 3). This effect was specific to the 
SWCNT /siTox complex, as none of the controls 
showed decreased cell viability. We conclude that the 
preparative sonication does not damage the siRNA 
and that siRNA is delivered into cells by pristine 
SWCNTs in a biologically active form. It is notable 
that serum did not inhibit the transfection process.
MiaPaCa-HRE cells were treated with SWCNTs 
complexed with either an siRNA specifi cally targeting 
HIF-1  (siHIF), or a non-targeting siRNA (siSC), at 
final concentrations of 3 mg /L SWCNTs and 5 μM 
siRNA. The choice of fi nal siRNA concentration was 
based on the initial siRNA concentration suspended 
in the siRNA buffer and probably exceeded the 
actual concentration of siRNA complexed to and 
taken into cells by SWCNTs. Treated cells were 
incubated under normoxic conditions at 37 °C for 
72 h and then transferred into a hypoxic chamber 
(1% oxygen) for an additional 18 h. HIF-1  activity 
was found to be significantly inhibited in cells 
treated with the SWCNT-siHIF-1  complex, but 
unchanged in cells treated with the SWCNT /siSC 
complex (Fig. 4 (a)). We confirmed by Western blot 
Figure 3 Pristine SWCNTs deliver biologically active siRNA into 
MiaPaCa-HRE pancreatic cancer cells. SWCNTs solubilized with either 
Tox siRNA (SWCNT / siTox), non-targeting siRNA(SWCNT /SC) or 10% 
FCS (SWCNTs), buffer alone or free Tox siRNA (siTox), were added to 
cells in growth media containing 10% FCS and incubated at 37 °C 
for 72 h prior to determination of cell viability
2.4   RNAi response induced by siRNA delivery 
into cells by pristine SWCNTs
We next investigated whether SWCNT /siRNA 
complexes could activate a specific RNAi response. 
For this our model was the MiaPaCa-HRE pancreatic 
cancer cell line (see Experimental section). Changes in 
HIF-1  activity can be accurately monitored in these 
cells by measuring the levels of luciferase expression. 
Figure 4 siRNA delivered into cells by pristine SWCNTs induces the 
RNAi response. Complexes of either SWCNT /non-targeting siRNA 
(siSC) or SWCNT / siRNA targeting HIF-1  (siHIF-1 ) were added to 
cells growing in normal media containing 10% FCS. Non-transfected 
parental cells (control) and siRNA transfected cells were incubated 
under normoxic conditions at 37 °C for 72 h and under hypoxic 
conditions (1% oxygen) at 37 °C for 18 h. HIF-1  activity was 
determined by the luciferase assay (a) and HIF-1  protein expression 
by Western blot (b) 
（a）
（b）
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that the inhibition of HIF-1  activity was the result 
of knockdown of the protein (Fig. 4(b)). The loss of 
HIF-1  activity and protein knockdown correlated 
well in a concentration-dependent manner. Because 
knockdown of the HIF-1  protein was observed only 
in cells treated with SWCNT /siHIF-1  complexes, we 
conclude that siRNAs retain their ability to induce 
a specifi c RNAi response after delivery into cells by 
complexation with pristine SWCNTs.
2.5   RNAi response in multiple cell types induced 
by SWCNT /siRNA complexes
We next added SWCNT /siRNA complexes to cultures 
of pancreatic cancer cells (MiaPaCa2), breast cancer 
cells (MCF-7, MDA-MB-231), and ovarian cancer cell 
line (RGM1) to determine whether SWCNTs could 
deliver siRNA into a wide range of cell types to 
induce the RNAi response. We observed (Fig. 5) that 
non-targeting siRNA (siSC) demonstrated negligible 
toxicity to the cancer cells tested while siTox and 
siKif11 both induced cell death in transfected cells. 
siRNA targeting KIf11 is a toxic siRNA commonly 
used to confirm transfection efficiency.  Our 
observation that delivery of siKif11 into cancer cells 
was toxic to these cells suggests that SWNCTs have 
the potential to function as a serum-insensitive, wide 
range transfection agent for delivery of siRNA into 
cancer cells to induce the RNAi response. 
2.6   Inhibition of HIF-1  activity in a xenograft 
mouse tumor by intratumoral administration of 
SWCNT /siRNA complexes
We used a xenograft  mouse tumor model to 
investigate the ability of SWCNT /siHIF complexes to 
inhibit HIF-1  activity in vivo. The siRNA buffer used 
to generate the SWCNT /siRNA complexes for the in 
vitro studies contains potassium and cannot be used 
in in vivo studies. We therefore selected 0.9% saline 
solution as our alternative to the siRNA buffer. To 
demonstrate that we can achieve a similar biological 
outcome using SWCNT /siRNA complexes in saline, 
complexes in 0.9% saline were prepared at several 
concentrations as described for the siRNA buffer 
and added to MiaPaCa-HRE pancreatic cancer cells 
growing in normal media containing 10% FCS. In this 
experiment we used siRNA targeting polo-like kinase 
1 (PLK1), a protein that plays an important role in 
the G2-M transition and whose silencing results in 
cell death. Determination of cell viability is a quick 
and efficient indicator of transfection efficiency 
as well as of induction of the RNAi response. We 
found that changing to the saline environment gave 
no significant change in biological activity of the 
SWCNT /siRNA complexes at the concentrations 
used for the animal study (Fig. 6 (a)). To study the 
effectiveness of targeting MiaPaCa-HRE cells in vivo, 
we subcutaneously injected cell suspensions into the 
right fl anks of 6 to 8-week-old female athymic nude 
mice (nu /nu). Activation of HIF-1  in the hypoxic 
environment of the growing tumor was confirmed 
by imaging the bioluminescence of luciferin. As 
MiaPaCa cell lines do not express HIF-2  these 
images allow us to effectively monitor HIF-1  activity 
in vivo in the xenograft mouse model (Figs. 6 (b) and 6 
(c); red indicates the highest luciferase concentration, 
followed by yellow and green; blue represents bleed-
through). We observed signifi cantly decreased tumor 
HIF-1  activity in mice treated with SWCNT /HIF 
complexes compared to those treated with complexes 
comprising either the control SWCNT /siRNA 
Figure 5 siRNA delivered into a range of cancer cells by pristine 
SWCNTs induces the RNAi response with similar efficiency. 
Complexes of either SWCNT /non-targeting siRNA (siSC), SWCNT /
siRNA targeting Kif11 (siKif11) or SWCNT / siRNA Tox (siTox) at a fi nal 
concentration of 5 mol /L were added to cells growing in normal 
media containing 10% FCS. Cells were incubated at 37 °C for 72 h. 
Cell viability was determined by the WST-1 assay
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(p<0.01 to p<0.05) or HIF-1  siRNA alone (Fig. 6 
(d)). However, no suppression of tumor volume 
was observed (Fig. 6 (e)), a result that we attribute 
to incomplete inhibition of HIF-1 . To test this 
possibility, we carried out an ex vivo experiment in 
which MiaPaCa-HRE parental cells, cells transfected 
with a control SWCNT /siRNA complex,  and 
SWCNT /siHIF  complex were grown in tissue culture 
for 24 h prior to being injected subcutaneously into 
mice. Tumor growth was monitored over a period of 
33 days. We observed that tumors generated by the 
parental cells and those transfected with the control 
siRNA grew similarly and at a faster rate compared 
to tumors transfected with the siRNA targeting 
HIF-1  (Data not shown). An initial period of growth 
inhibition in this latter group accounted for its slow 
rate of growth compared to the other two groups. As 
the tumors were harvested on day 33, together with 
the fact that protein silencing by siRNA is a transient 
effect usually lasting up to a week, it was no surprise 
to us that we failed to observe any significant 
difference in the levels of HIF-1  between the three 
groups. We have shown that transfecting cells for 
periods longer than 6 h with siRNA /SWCNT results 
in both a signifi cant uptake of the complexes into the 
cells (Fig. 2) and silencing of HIf-1  expression (Fig. 
4 (b)) and conclude therefore, that the initial growth 
inhibition observed in our ex vivo study was most 
Figure 6 Intratumor administration of SWCNT / siRNA complexes inhibits HIF-1  activity in a xenograft mouse tumor. (a) A range of 
concentrations of SWCNT-siPLK complexes in a 0.9% saline solution were added to MiaPaCa-HRE pancreatic cancer cells growing in media 
containing 10% FCS. Cell viability was determined 72 h after treatment. At average tumor volumes of 150 200 mm3, tumor-bearing mice were 
imaged using xenogeny prior to the addition of luciferin (b) and 5 min after the addition of luciferin (c). (d) Tumor-bearing mice were divided 
into three groups (eight mice per group) and given intratumoral injections of either siRNA targeting HIF-1  alone (siHIF-1 ), a non-targeting 
siRNA complexed to SWCNTs (SWCNT / siSc), or siRNA targeting HIF-1  complexed to SWCNTs (SWCNT-siHIF) twice per week for 3 weeks (on 
days marked by arrows). Changes in HIF-1  activity within the tumor were monitored by imaging for luciferase expression twice per week for the 
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probably due to the complete inhibition of HIF-1 . 
The awareness of the clinical relevance of carbon 
nanotubes has raised questions about its toxicity. 
The evidence of toxicity is mainly derived from 
studies focused on the adsorption of large carbon 
nanostructures via inhalation or dermal exposure [38]. 
In addition, carbon nanoparticles and multiwalled 
nanotubes with diameters in excess of 20 nm, have 
inhibited the growth of cultured human lung cancer 
cells [28]. Surprisingly, even at high concentrations, 
toxicity has not been observed following intravenous 
administration of either pristine or functionalized 
SWNTs [39 42]. No mortality or loss of mass of 
mice as well as no evidence of toxicity in tissues and 
organs were observed in these studies that ranged in 
time from 24 h to 6 months after treatment. 
Our results demonstrate that siRNA can be used 
to solubilize pristine SWCNTs and that noncovalent 
SWCNT /siRNA complexes can transfect cancer cells 
and effectively silence a targeted gene in cell culture 
and also in tumors in vivo. The use of synthetic siRNA 
serves as a powerful tool to silence target genes with 
a high degree of specificity and is a potential novel 
approach for targeted cancer therapy [15]. In this 
study we used many different siRNA sequences to 
complex the pristine SWNCTs, and observed that 
irrespective of their nucleotide sequences these 
siRNA solubilized the SWCNTs equally effectively. 
This differs from other reports that the ability of 
single-stranded DNA to solubilize pristine SWNTs 
is dependent on the GC content of the nucleotide 
sequence. (Bruce Weisman, unpublished results). 
Whether these differences are associated with the 
use of single-stranded or double-stranded nucleotide 
sequences remains to be determined however. 
Efficient intracellular transport and delivery of 
siRNA are critical to the potency and in vivo therapeutic 
activity of RNAi. We observed internalization of the 
SWCNT-siRNA complex in about 30% of the treated 
cells 1 h after addition of the complex to cells growing 
in media containing 10% serum. By 3 h post treatment, 
internalized SWCNTs were observed in more than 
90% of cells and the number of internalized SWCNTs 
per cell increased further after 6 h. These findings 
suggest the capability of introducing siRNA into 
nearly all of the cells in a culture, a result usually 
achieved only through viral gene delivery. Whereas 
viral vectors can have the drawbacks of inducing 
immune responses, inflammation, and (potentially) 
oncogenic effects [43], the SWCNT delivery agent 
appears nontoxic to most cells. 
It is noteworthy that the delivery of siRNA by 
SWCNTs occurred even in the presence of serum. 
Serum proteins can bind to the surface of SWCNTs 
in a non-specific manner and this spontaneous 
adsorption is usually seen on acid-oxidized water 
soluble SWCNTs [16, 44]. Small proteins such as 
streptavidin (60 kD) adsorb more readily to the 
sidewalls of individual SWCNTs while large proteins 
such as fibrinogen (340 kD) adsorb poorly [45]. In 
addition, the binding of proteins to carbon nanotubes 
depends on the physical organization of the 
nanotubes. Fibrinogen has a strong binding affi nity to 
the surface of nonwoven nanotubes whereas albumin, 
even at high concentrations failed to bind to this 
surface [45]. Studies with ssDNA have suggested that 
the flexibility of this molecule allows it to find low 
energy conformations that maximize base nanotube 
stacking interactions while exposing the hydrophilic 
sugar phosphate backbone to the water [29]. We 
hypothesize that the inability of serum proteins to 
significantly influence the activity of the SWCNT /
siRNA could be due either to the weak binding of 
the proteins to the pristine nanotubes or the inability 
of the proteins to displace siRNA from the nanotube 
surface, possibly because the hydrophilic sugar 
phosphate backbone can block protein adsorption. 
Further studies will be needed to clarify the kinetic 
and thermodynamic factors controlling interactions 
of serum proteins with SWCNT /siRNA complexes. 
Lipid reagents have successfully been used to 
deliver siRNA into cancer cells. When we compared 
the effectiveness of SWCNTs and lipid reagents as 
delivery agents of siRNA we observed that they were 
comparable in their ability to delivery siRNA into cells 
to induce the RNAi response. There were however 
significant differences. Commercial lipid reagents 
are very cell line specific and to obtain optimum 
transfection conditions with minimum toxicity requires 
selecting the best reagent from a panel of lipid reagents. 
The SWCNTs are much less cell line dependent and 
have negligible toxic effects on most cell lines. In 
289Nano Res (2009) 2: 279 291
addition, lipid reagent transfections have to be carried 
out in the absence of serum which is toxic to cells, 
while SWCNTs transfections can be carried out in the 
presence of serum. This suggests that SWCNTs have 
the potential to be developed into a universal delivery 
agent for siRNA. 
The simple sonication-based protocol for forming 
SWCNT /siRNA complexes evidently does not 
functionally damage the siRNA, as cells exposed 
to the complexes display a clear RNAi response. 
We found that both HIF-1  activity and protein 
levels were lowered by approximately 70% to 
80% when the pristine SWCNTs delivered siRNA 
targeting HIF-1  mRNA into the host cancer cells. An 
intriguing question arises as to how the complexed 
siRNA induces the RNAi response. One possibility 
is that siRNA dissociates from the SWCNTs inside 
the cell; another is that siRNA molecules retain their 
RNAi activity while still complexed with nanotubes. 
Additional research is needed to resolve this 
important question.
Although we chose to target HIF-1  in these 
studies, the approach can be applied to other targets 
for RNAi. As these SWCNT-siRNA complexes 
can enter most cells in their present composition 
but appear to be rather rapidly cleared from the 
blood, we used direct intratumoral injection to 
demonstrate that pristine SWCNTs can deliver HIF-1
-targeting siRNA into tumor cells. Further studies 
are underway to prepare SWCNT-siRNA complexes 
that can function therapeutically following systemic 
administration. 
3. Conclusions
We have demonstrated a simple and inexpensive 
method, involving no chemical reactions, for 
preparing soluble complexes of siRNA and pristine 
SWCNTs. The complexes are effective in silencing 
target genes both in vitro and in vivo with a high 
degree of specificity and minimal toxicity. We have 
demonstrated that our complexes of siRNA and 
pristine SWCNTs can transfect and induce the RNAi 
response in a range of cancer cells. This promising 
technology deserves further investigation for use as a 
therapeutic strategy against multiple tumor types. 
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